Archives of Internal Medicine · 2008 · 321 citations · 33 references
PharmacyInfectious DiseasesInternal MedicineAntimicrobial PharmacotherapyAntimicrobial StewardshipAntibiotic ProphylaxisAntimicrobial Agent SelectionAntimicrobial ProphylaxisAntimicrobial TherapyGuideline ImplementationProphylactic Antimicrobial UseAcute Upper Respiratory Tract InfectionsAntibiotic Prophylaxis AdministrationPrimary Care PathwaysProcalcitonin-guided Antibiotic De-escalationProphylactic Antibiotic TherapyRespiratory Tract Infection Treatment
BACKGROUND: Acute respiratory tract infections are the most common reason for antibiotic therapy in primary care despite their mainly viral etiology. A laboratory test measuring procalcitonin levels in blood specimens was suggested as a tool to reduce unnecessary prescribing of antibiotics. We consider whether antibiotic therapy guided by procalcitonin reduces the use of antibiotics without increasing the restrictions experienced by patients by more than 1 day. METHODS: Fifty-three primary care physicians recruited 458 patients, each patient with an acute respiratory tract infection and, in the physician's opinion, in need of antibiotics. Patients were centrally randomized to either a procalcitonin-guided approach to antibiotic therapy or to a standard approach. For patients randomized to procalcitonin-guided therapy, the use of antibiotics was more or less strongly discouraged (procalcitonin level, < or =0.1 or < or =0.25 microg/L, respectively) or recommended (procalcitonin level, >0.25 microg/L). Follow-up data were collected at 7 days by treating physicians and at 14 and 28 days by blinded interviewers. RESULTS: Adjusted for baseline characteristics, the mean increase at 14 days in days in which activities were restricted was 0.14 with procalcitonin-guided therapy (95% confidence interval [CI], -0.53 to 0.81 days), which met our criterion of an increase in days in which activities were restricted by no more than 1 day. With procalcitonin-guided therapy, the antibiotic prescription rate was 72% lower (95% CI, 66%-78%) than with standard therapy. Both approaches led to a similar proportion of patients reporting symptoms of ongoing or relapsing infection at 28 days (adjusted odds ratio, 1.0 [95% CI, 0.7-1.5]). CONCLUSIONS: As an adjunct to guidelines, procalcitonin-guided therapy markedly reduces antibiotic use for acute respiratory tract infections in primary care without compromising patient outcome. In practice, this could be achieved with 1 to 2 procalcitonin measurements in patients for whom the physician intends to prescribe antibiotics.
33
Reporting of Noninferiority and Equivalence Randomized Trials
Gilda Piaggio, Diana R Elbourne, Stuart Pocock et al. · JAMA · 2012 · 2.4K citations
Mirjam Christ‐Crain, Daiana Jaccard-Stolz, Roland Bingisser et al. · The Lancet · 2004 · 1.1K citations
Trials to assess equivalence: the importance of rigorous methods: Fig 1
Byron Jones, Philip Jarvis, John A. Lewis et al. · BMJ · 1996 · 1K citations